Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) saw some unusual options trading on Monday. Stock traders acquired ...

Investment analysts at William Blair issued their FY2029 earnings per share estimates for shares of Neumora Therapeutics in a ...

It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on the announcement of a study failure, while Hoth Therapeutics HOTH gained on ...

BofA analyst Geoff Meacham lowered the firm’s price target on Neumora Therapeutics (NMRA) to $7 from $22 and keeps a Buy rating on the shares.

Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -74.98%. The profit margin, also known as the revenue ratio or gross profit ...

J.P. Morgan analyst Tessa Romero has maintained their neutral stance on NMRA stock, giving a Hold rating yesterday.Don't Miss Our New Year's ...

Neumora Therapeutics Inc (NMRA) stock saw a modest uptick, ending the day at $2.17 which represents a slight increase of $0.20 or 10.15% from the prior close of $1.97. The stock opened at $2.23 and ...

Neumora Therapeutics (NMRA) announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive disorder. The KOASTAL-1 Study is the first of three replicate Phase ...

Neumora Therapeutics shares plunged more than 80% on Thursday after its lead drug candidate failed to help patients with ...

Neumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRA ...